Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Atlas of Genetics and Cytogenetics in Oncology and Haematology INIST-CNRS OPEN ACCESS JOURNAL Solid Tumour Section Review Fallopian tube tumors: an overview Roland Gregor Stein, Joachim Diessner, Arnd Hönig, Jörg Wischhusen, Johannes Dietl Wurzburg University Hospital, Department of Obstetrics and Gynecology, Josef-Schneider-Str. 4, 97080 Wurzburg, Germany (RGS, JD, AH, JW, JD) Published in Atlas Database: March 2013 Online updated version : http://AtlasGeneticsOncology.org/Tumors/FallopTubTumID5279.html DOI: 10.4267/2042/51820 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2013 Atlas of Genetics and Cytogenetics in Oncology and Haematology Inevitably, the considerable overlap between ovarian and fallopian tube carcinomas warrants some coverage of ovarian cancer in this context. Nevertheless, as ovarian carcinomas constitute a well-accepted clinical entity (irrespective of their potential origin from the fallopian tube) they shall largely be dealt with in a separate place. Identity Introduction This article shall give an overview of different tumors occurring in the fallopian tube. Though being a very rare location of primary or exclusive tumor manifestation, the fallopian tube is now receiving increased attention in gynecological oncology since considerable evidence suggests that it represents the site-of-origin of many (if not most) serous pelvic carcinomas (Folkins et al., 2009; Dietl and Wischhusen, 2011; Dietl et al., 2011; Seidman et al., 2011; Vang et al., 2013). Disease definition A tumor is classified as primary fallopian tube tumor when it is either restricted to this anatomical structure, or when the fallopian tube is most affected whereas colocations such as ovary and uterus show lesser involvement or a different histology (Alvarado-Cabrero et al., 2003; Folkins et al., 2009). As recent data indicate that the fallopian tube is the site-of-origin of serous pelvic carcinomas (Folkins et al., 2009; Dietl and Wischhusen, 2011; Dietl et al., 2011; Seidman et al., 2011; Vang et al., 2013), histological assessment of the respective involvement of ovaries and fallopian tubes may not be sufficient to distinguish between advanced stages of fallopian tube and ovarian carcinomas (Kosary and Trimble, 2002). Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) Classification Note Solid fallopian tube tumors can be subcategorized based on origin and behavior. The WHO classification distinguishes several groups of solid tumors of the fallopian tube (Alvarado-Cabrero et al., 2003) shown in Figure 1. Classification Staging Malignant tumors of the fallopian tube are classified according to the "Union International contre le cancer" (UICC) and the "Fédération internationale de Gynécologie et d'Obstétrique" (FIGO, Table 1 and 2). The TNM classification is based on clinical and pathological findings whereas the FIGO classification requires a surgical staging (UICC, 2009; AJCC, 2010). According to the TNM classification, the carcinomas of the fallopian tube approximate different stages (Table 2). 773 Fallopian tube tumors: an overview Stein RG, et al. Figure 1: WHO Classification of solid tumors of the fallopian tube (Alvarado-Cabrero et al., 2003). Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 774 Fallopian tube tumors: an overview Stein RG, et al. Table 1: TNM and FIGO Classification of carcinomas of the fallopian tube (UICC, 2009). Table 2: Staging of fallopian tube carcinomas (UICC, 2009). Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 775 Fallopian tube tumors: an overview Stein RG, et al. of symptoms - intermittent profuse serosanginous vaginal discharge, colicky pain relieved by discharge, abdominal or pelvic mass - is reported in only 15% of all patients (Ajithkumar et al., 2005). 5% of the patients show a hydrops tubae profluens. Fallopian tube carcinomas are diagnosed at earlier stages than epithelial ovarian cancers (Peters et al., 1988; Rose et al., 1990; Gadducci et al., 2001; Pectasides et al., 2006). 10-36% show positive PAP smear tests with intermittent detection of abnormal, suspicious or poorly differentiated cells or glands (Ajithkumar et al., 2005). In 80% of the advanced stages, peritoneal metastases occur (Levite et al., 2001). Also haematogenous or transluminal metastases were found (Yoonessi, 1979). Bilateral tubal involvement has been described in 1027% of fallopian tube carcinomas (Schiller and Silverberg, 1971; Hirai et al., 1989; Rose et al., 1990; Alvarado-Cabrero et al., 1999; Rosen et al., 1999; Gadducci et al., 2001). The higher rate of lymph node metastases in comparison to ovarian cancer should be considered, as staging of fallopian tube carcinomas is surgical. Compared to epithelial ovarian cancer, fallopian tube carcinomas show a higher rate of retroperitoneal and distant metastases (Yoonessi, 1979; McMurray et al., 1986; Maxson et al., 1987; Asmussen et al., 1988; Peters et al., 1988; Gadducci et al., 2001). Para-aortic lymph node metastases were detected in 33% of patients (Tamimi and Figge, 1981). Another study revealed 42-59% lymph node metastases in routine lymphonodectomy with equal involvement of paraaortic and pelvic lymph nodes (Ajithkumar et al., 2005). If routine lymphonodectomy is not performed, a surgical understaging may occur. Overall, 20-25% of patients with fallopian tube carcinomas showed FIGO stage I, 20% stage II, 45-50% stage III and 5-10% stage IV (Ajithkumar et al., 2005). Ectopic β-HCG-production was reported in two cases of serous or undifferentiated fallopian tube carcinomas (Carapeto et al., 1978; Alvarado-Cabrero et al., 1999). These tumors contained syncytiotrophoblast-like cells. Case reports about renin-producing or alpha fetoprotein (AFP)-producing tumors have been published (Aoyama al., 1996; Zabernigg et al., 1997). Fallopian tube carcinomas show frequent expression of CA-125 (Puls et al., 1993). Hence, >80% of the patients show elevated CA-125 serum levels (McMurray et al., 1986; Ajithkumar et al., 2005) that correlate significantly with disease-free and overall survival (Rosen et al., 1999; Ajithkumar et al., 2005). Adenomyomas can also cause elevated CA-125 levels and small volumes of serous ascites. With some limitations, CA-125 may thus be considered as suitable tumor marker for use in cancers of the fallopian tube (Baekelandt et al., 2000). Clinics and pathology Etiology The etiology of primary fallopian tube tumors is unknown. Multiparity seems to be protective (Riska et al., 2003), pregnancies and oral contraceptives decrease the risk (Inal et al., 2004). Neither age, nor weight, education level, pelvic inflammatory disease, infertility, previous hysterectomy or endometriosis show significant correlations especially with fallopian tube carcinomas (Henderson et al., 1977; Demopoulos et al., 2001; Inal et al., 2004). Demographic distribution is similar to ovarian cancer, and the highest incidence was found in white, non-Hispanic women and women aged 60-79. However, recent evidence suggests tubal cancer to be much more frequent (Stewart et al., 2007; Piek et al., 2008). Epidemiology Epidemiological data on malignant fallopian tube tumors are adequate, even though only 0.3-1.1% of all gynecological malignancies are typically classified as primary fallopian tube carcinomas (Baekelandt et al., 2000), mostly adenocarcinomas (Schneider et al., 2000). In the U.S., the incidence is about 3.6 per million women per year (Rosenblatt et al., 1989). Stage-adjusted survival rates are generally better than for epithelial ovarian carcinoma (Kosary and Trimble, 2002). Underestimation of the real incidence might be due to fallopian tube carcinomas being mistaken for ovarian cancers (Woolas et al., 1994) which show a significantly higher prevalence. Still, Riska and colleagues reported an increasing incidence of fallopian tube carcinomas from 1.2 per million per year for 19531957 to 5.4 per million per year from 1993-1997 (Riska et al., 2003). Clinics Clinical presentation Patients with benign tumors of the fallopian tube are often asymptomatic or report local pain. The tumors are incidentally found during operations for other indications (Etoh et al., 2012). Benign tumors can abet tubal torsions (Alvarado-Cabrero et al., 2003). Especially papillomas can obstruct the fallopian tube (Gisser, 1986). Obstruction of the fallopian tube can cause infertility (Heller et al., 1991; Heatley, 2001). Primary fallopian tube carcinomas most frequently occur between the fourth and sixth decade of life with a mean patient age of 55 years (Boutselis and Thompson, 1971; Sedlis, 1978). Stewart et al. found an incidence rate of 0.41 per 100000 women with highest incidence rates in women aged 65-69 in a study including 3051 cases of primary fallopian tube carcinomas (Stewart et al., 2007). Symptoms are very diffuse, the Latzko triad Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 776 Fallopian tube tumors: an overview Stein RG, et al. Figure 2: Histology of an invasive serous-papillary adenocarcinoma of the fallopian tube. a: Tumor formation in the tubal wall. b shows 200 fold magnification with gland formation (*). c: Metastasis in adipous tissue. d: Immunohistochemistry for Ki67 with nuclear positivity. e and f: Immunohistochemistry for p53 also with nuclear positivity. Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 777 Fallopian tube tumors: an overview Stein RG, et al. Figure 3: a: In this H&E staining, the STIC cells show polymorphic nuclei and a multilayer epithelium (arrowheads) compared with normal tubal epithelium (arrows). b: Distinct transition from normal tubal epithelium to p53 positive STIC (p53 immunohistochemistry). c: Invasive fallopian tube carcinoma (arrowheads) next to STIC formation (arrows, H&E). The average lead time of increasing CA-125 levels versus clinical or radiological diagnosis of recurrence is three months with a range from 0.5 to 7 months (Ajithkumar et al., 2005). Fallopian tube carcinomas can cause paraneoplastic symptoms. For example, a paraneoplastic cerebellar degeneration (PCD) with Anti-Yo antibodies is associated with fallopian tube carcinomas (Levite et al., 2001; Tanaka et al., 2005; Selby et al., 2011). Cabrero et al., 2003). In fallopian tubes resected post partum, few metaplastic papillary tumors were detected (Saffos et al., 1980; Keeney and Thrasher, 1988; Bartnik et al., 1989). These tumors consist of papillae lined by epithelium displaying patterns of a serous borderline tumor. The cells can be positive for intracellular mucin (Alvarado-Cabrero et al., 2003). Adenomyomas consist of bundle-like growing leiomyoma cells and sometimes endometrial tissue remnants. Endometrioid polyps occur in the interstitial part of the tube attached to the intratubal epithelium and sometimes cause infertility (Heller et al., 1991; Heatley, 2001). Cystadenofibromas can show vimentin-cytokeratincoexpression. Further, diffuse apical epithelial membrane antigen (EMA) immunoreactivity occurs. Gürbüz et al. suggest that tumors are derived from embryonic remnants of the Müllerian duct (Gürbüz and Ozkara, 2003). Borderline tumors of the fallopian tube occur very rarely and can show serous, mucinous or endometrioid differentiations. Histological features resemble those in borderline tumors of the ovary (Alvarado-Cabrero et al., 1997). Mucinous tumors of the fallopian tube can Pathology Benign tumors Benign tumors are often solid and clearly delimited. They arise at the intraluminal or serosal surface of the fallopian tube. Papillomas show fibrovascular stacks with epithelial lining. They can obstruct the fallopian tube (Gisser, 1986). Adenofibromas and cystadenofibromas occur between the third and eighth decade. They remain asymptomatic and are diagnosed incidentally during other operations (Zheng et al., 1996). Macroscopically, these tumors grow to 0.5-3cm and can be intraluminal or at the serosa surface as well as at the fimbriae. They show a stromal and a papillary structured fraction (Alvarado- Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 778 Fallopian tube tumors: an overview Stein RG, et al. development and already detectable in the STIC (Kuhn et al., 2010). As the post-reproductive fallopian tube lacks physiological functions and also causes complications such as hydrosalpinx, Dietl et al. suggested combined hysterosalpingectomy instead of simple hystercectomy or salpingectomy as a recommendable method for sterilization in clinical routine (Dietl and Wischhusen, 2011; Dietl et al., 2011). Invasive carcinoma All tumor subtypes in the ovaries are also known in the fallopian tube, with serous carcinomas being most frequent. In a series of 105 fallopian tube carcinomas Alvarado-Cabrero et al. found the following distribution of different histologies: About 50% were serous, 25% endometrioid, 20% transitional cell or undifferentiated carcinomas and 5% were of other subtypes (Alvarado-Cabrero et al., 1999). Serous adenocarcinomas are generally invasive with 50% G3 tumors (Alvarado-Cabrero et al., 1999). Sometimes immune cell invasion disguises the tumor as salpingitis (Cheung et al., 1994). Mucinous adenocarcinomas, a very rare entity, are often associated with other mucinous carcinomas of the female genital tract or the appendix (Seidman, 1994). Endometrioid adenocarcinomas are very often noninvasive or superficially invasive and show a favorable prognosis (Navani et al., 1996). A part of those tumors displays characteristics of the wolffian adnexal tumor (Daya et al., 1992; Navani et al., 1996). Clear cell adenocarcinomas account for 2-10% of all fallopian tube carcinomas (Voet and Lifshitz, 1982; Hellstrom et al., 1994; Alvarado-Cabrero et al., 1999). Transitional cell carcinomas are rare in the genital tract. Still, the frequency between 11 and 43% of all fallopian tube carcinomas makes it an important locus-specific entity (Uehira et al., 1993; Alvarado-Cabrerog et al., 1999). Undifferentiated carcinomas lack any patterns of squamous cells or glandular cells but instead contain multinuclear giant cells (Alvarado-Cabrero et al., 1999). Lacy et al. reported immunohistochemical positivity for c-erbB-2 (HER-2/neu) overexpression in 26% and p53 positivity in 61% of all cases in a cohort of 43 patients with fallopian tube carcinoma. There was not significant correlation with survival (Lacy et al., 1995). Ovarian cancer in comparison also shows c-erbB-2 (HER-2/neu) positivity in about 29% of all cases (Lanitis et al., 2012). Others, in contrast, described a correlation between p53 immunohistochemical positivity and shorter survival (Zheng et al., 1997; Rosen et al., 2000). FIGO stages, however, did not correlate with survival in this same cohort of 63 patients (Rosen et al., 2000). Zheng et al. investigated the correlating immunohistochemistry and polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) for p53 in 52 cases of fallopian tube carcinoma and 10 normal fallopian tubes be associated with pseudomyxoma peritonei (McCarthy and Aga, 1988), other mucinous lesions or PeutzJeghers-Syndrome (Seidman, 1994). There are also reports about adenofibroma with borderline malignancy. The prognosis seems to be favorable (Zheng et al., 1996; Alvarado-Cabrero et al., 1997). Precursor lesions: Intraepithelial carcinoma Non-invasive carcinomas of the fallopian tube were formerly known as "carcinoma in situ". This term should be abandoned as it implies restricted local tumor formation. Intraepithelial carcinoma cells can, however, form implants on the ovarian surface and the peritoneum. Recent publications highlight the fallopian tube as likely site-of-origin of primary pelvic serous carcinomas detected in the fallopian tube, the ovary or the peritoneum (Folkins et al., 2009; Dietl and Wischhusen, 2011; Dietl et al., 2011; Seidman et al., 2011; Vang et al., 2013). Serous tubal intraepithelial carcinomas (STIC) as well as endometrioid intraepithelial carcinomas (EIC) are thus considered as precursor lesions (Ambros et al., 1995; Carlson et al., 2008). This hypothesis is supported by findings from Colgan et al. who found a high frequency of precancerous lesions in fallopian tubes from patients with BRCA gene mutations (Colgan, 2003). Lee and colleagues could detect mutant p53-signatures predominantly in epithelial cells at the fimbriated ends of fallopian tubes from patients with BRCA1 and 2 mutations. Moreover, the same signatures were also found in corresponding ovarian cancer tissues (Lee et al., 2007). Interestingly, Li-Fraumeni-Syndrome which is associated with p53 mutations and generally increased risk for serous carcinomas - does not correlate with a higher incidence of PPSC, especially fallopian tube carcinomas. Thus, it seems that other mutations e.g. those affecting BRCA are required to drive PPSC development (Xian et al., 2010). Kim and colleagues could prove by histology that serous epithelial cancers develop in the fallopian tubes of Dicer-PTEN-double-knockout mice. By histology and pathological behavior these tumors showed characteristic traits of serous epithelial ovarian cancer, even though oophorectomy was not protective. Instead, tumor development could be prevented by salpingectomy (Kim et al., 2012). Furthermore, in prophylactic salpingo-oophorectomy specimen, occult carcinomas are more frequent in the fallopian tube than the ovary (Vang, 2011). While carrying the potential of invasiveness, the STIC cells grow sparing the tubal stroma. Figure 3 focusses on the STIC with its distinct cellular alterations such as polymorphic nuclei, multilayer epithelium and atypic mitoses. Figure 3d also shows an invasive fallopian tube carcinoma with an adjoining STIC. In clinical studies, a frequent coexistence of pelvic serous carcinoma and tubal intraepithelial carcinomas was found in unselected (Przybycin et al., 2010) and BRCA mutated patients (Kindelberger et al., 2007). Shortening of telomeres is another early event in PPSC Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 779 Fallopian tube tumors: an overview Stein RG, et al. fallopian tube (Dekel et al., 1986). About 40% of these go along with adnexal tumors (Ober and Maier, 1981). In the fallopian tube, hydatiform moles can histologically correspond to a complete, partial or invasive mole (Alvarado-Cabrero et al., 2003). Placental site nodules as non-neoplastic proliferation of intermediate trophoblast can occur (Alvarado-Cabrero et al., 2003). Intermediate trophoblast tumors can be either benign or malignant (Kurman et al., 1976). Only one case of malignant placental site trophoblastic tumor has been reported in the fallopian tube (Su et al., 1999). Lymphoid and haematopoietic tumors Malignant lymphoma and leukemia mostly show an involvement of the ipsilateral ovary (Osborne and Robboy, 1983). 25% of patients with ovary lymphomas had a Burkitt-lymphoma or Burkitt-like lymphoma or a diffuse large-cell lymphoma. Metastatic tumors For 89% of secondary tumors in the fallopian tube, the primary tumor was assigned to be of ovarian origin (Woodruff and Julian, 1969). Considering the ongoing paradigm shift which proposes that serous ovarian carcinomas likely originate from the fallopian tube, these figures have to be reconsidered. Many of these tumors may have originated from the fimbriated end of the fallopian tube with a secondary manifestation in the ovary. and found that p53 alterations already occur at early stages suggesting a role in early tumor progression (Zheng et al., 1997). Chung and colleagues found that survival neither correlated with immunohistochemical p53 positivity nor with cMyc overexpression (which occured in 61%). However, the statistical power of this study was limited by the small cohort of 18 patients (Chung et al., 2000). Hence, it did not challenge larger studies which proposed that p53 might have an important role especially in familial BRCA-associated cases of fallopian tube carcinomas. Figure 2 shows different pathohistological aspects of a serous adenocarcinoma of the fallopian tube. Mixed epithelial-mesenchymal tumors The least common site for malignant Müllerian mixed tumor (carcinosarcoma, metaplastic carcinoma) is the fallopian tube accounting for only 4% of all cases. The prognosis of these mostly postmenopausal patients is poor (Hanjani et al., 1980). In the literature, only one adenosarcoma has been described in the fallopian tube (Gollard et al., 1995). Soft tissue tumors Leiomyosarcomas are very rare as only 37 cases have been reported in 100 years (Jacoby et al., 1993). Mesothelial tumors Adenomatoid tumors mostly occur in middle-aged or elderly women (Inoue et al., 2001). In most cases, they remain asymptomatic but can also occlude the lumen. Often, they show gland-like structures with a lining of flat to cuboidal cells (Stephenson and Mills, 1986). Germ cell tumors Until 2003, 50 cases of mature or immature teratoma were reported (Alvarado-Cabrero et al., 2003). For malignant mixed germ cell tumors of the fallopian tube, only one single case was published (Li et al., 1999). Trophoblastic tumors Only about 4% of choriocarcinomas occur in the Treatment Surgical therapy: For fallopian tube tumors and especially for carcinomas, surgical removal is the first line treatment. Whereas benign tumors can usually be resected completely, the approach for fallopian tube carcinomas should be the same as for epithelial ovarian cancer with the aim of complete resection or at least maximum tumor debulking. Table 3: Postoperative treatment of fallopian tube carcinoma (Pectasides et al., 2006). Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 780 Fallopian tube tumors: an overview Stein RG, et al. platinum-pretreated patients also highlights the role of Paclitaxel (Tresukosol et al., 1995; Baekelandt et al., 2000; Ichikawa et al., 2000; Gemignani et al., 2001). After review of the literature and according to the U.S. guidelines, Pectasides and colleagues suggested an adjuvant standard treatment shown in table 3 (Pectasides et al., 2006). For the treatment of relapse, platinum-sensitive tumors (relapse after more than 6 months) receive a reinduction with platinum with or without Paclitaxel, whereas patients with platinum-refractory (relapse during therapy) or platinum-resistant tumors (relapse <6 months) receive Topotecan or liposomal Doxorubicin (Pectasides et al., 2006). In epithelial ovarian cancer, Bookman and colleagues as well as Hoskins et al. treated patients with relapse after platinum- and Paclitaxel-based chemotherapy with Topotecan (Bookman et al., 1998; Hoskins et al., 1998). Also liposomal Doxorubicin can achieve response rates of 17-26% in patients who have relapsed after platinum- and Paclitaxel based chemotherapy (Muggia et al., 1997; Gordon et al., 2000). Recent data from the OCEANS trial revealed that addition of Bevacizumab to the combination of carboplatinum/gemcitabine increases the response rate and prolongs progression-free survival in patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer. Overall survival, however, remained unchanged (Aghajanian et al., 2012). Likewise, the CALYPSO trial which tested the combination of pegylated liposomal doxorubicin (PLD)/carboplatin with paclitaxel/carboplatin in platinum-sensitive ovarian cancer patients found a prolonged time to progression along with reduced side effects of PLD as compared to paclitaxel. Again, however, there was no effect on overall survival (Wagner et al., 2012). Still, an intermediate report from the AURELIA trial suggests that supplementation of chemotherapy with Bevacizumab might be highly beneficial for patients with platinum-resistant ovarian cancer (PujadeLauraine et al., 2012). Special focus should be placed on para-aortic and pelvic lymphadenectomy in regard to the higher rate of lymph node metastases (Yoonessi, 1979; McMurray et al., 1986; Maxson et al., 1987; Asmussen et al., 1988; Peters et al., 1988; Gadducci et al., 2001). Klein and colleagues found a significantly reduced median survival of 21 months versus 43 months in patients who had not undergone lymphadenectomy (Klein et al., 1999). Radiotherapy: Although radiotherapy for fallopian tube carcinomas could be considered, it is inferior to adjuvant platin compounds containing chemotherapy. Neither irradiation nor intraperitoneal instillation of radioisotopes could prevent relapse (Asmussen et al., 1988). A second look operation with pathological complete remission (pCR) is a predictor for longer survival. 50% of patients with surgical complete remission will ultimately relapse. Thus, second-look operations are not generally beneficial and hence no routine treatment (Takeshima and Hasumi, 2000). Adjuvant chemotherapy: Baekeland et al. found a 70% response rate to adjuvant platinum-containing chemotherapy in platinum-naive patients with median response duration of 12.5 months. They further suggested to refrain from postoperative radiation therapy due to its low efficacy and high rate of complications (Baekelandt et al., 2000). Kosary et al. gave the general recommendation to treat women with fallopian tube carcinomas like women with epithelial ovarian cancer, i.e. by surgical staging and debulking followed by adjuvant chemotherapy (Kosary and Trimble, 2002). In addition to platinum-based chemotherapy, also paclitaxel is becoming more and more important in the treatment of advanced fallopian tube tumors (Takeshima and Hasumi, 2000). Patients with early stages as IA and IB might not need adjuvant chemotherapy. For all higher stages, adjuvant combined chemotherapy is requested. Two randomized controlled trials (International Collaborative Ovarian Neoplasm 1 (ICON1) and Adjuvant Chemotherapy In Ovarian Neoplasm (ACTION)) compared platinum based adjuvant chemotherapy and mere observation after early stage ovarian cancer surgery and reported 5 year overall survival rates of 74% without and 82% with adjuvant platinum based chemotherapy (Trimbos et al., 2003). This could hint at a survival benefit being associated with adjuvant chemotherapy also for early stage fallopian tube carcinomas. Cisplatin based chemotherapy yielded response rates between 53 and 92 % (Deppe et al., 1980; Raju et al., 1981; McMurray et al., 1986; Maxson et al., 1987; Peters et al., 1988; King et al., 1989; Muntz et al., 1989; Barakat et al., 1993; Pectasides et al., 1994). Several studies also included Paclitaxel in the first line therapy (McMurray et al., 1986; Maxson et al., 1987; Muntz et al., 1991; Ben-Hur et al., 1999; Gemignani et al., 2001). For relapse therapy, data from epithelial ovarian cancer in Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) Prognosis Prognostic factors for early stage I carcinomas are depth of invasion into the tubal wall and tumor rupture during surgery. Even early stages tend to metastasize to the peritoneum (Baekelandt et al., 2000). The surgical stage is an independent prognostic factor (Alvarado-Cabrero et al., 1999; Baekelandt et al., 2000). Carcinomas of the fimbriae region are afflicted by a worse prognosis than carcinomas of the isthmic region (Alvarado-Cabrero et al., 1997). There are different results concerning the histological grading: Vaughan et al. found a significant correlation between grading and survival (Vaughan et al., 1998), Gadducci et al. could also find this in univariate but not 781 Fallopian tube tumors: an overview Stein RG, et al. in multivariate analysis (Gadducci et al., 2001). Grading further correlates with lymphogenous metastases (Klein et al., 1999). Lymphocytic infiltration of the tumor correlates with favorable outcome (Rosen et al., 1993). The role of DNA-ploidy is thought to be negligible (Klein et al., 2002). Fallopian tube carcinoma patients show an overall survival of 30-50% which is slightly better than the reported 25-40% for epithelial ovarian cancer (Momtazee and Kempson, 1968; Baekelandt et al., 1993; Barakat et al., 1993; Woolas et al., 1994; Alvarado-Cabrero et al., 1999; Piura and Rabinovich, 2000). The general 5-year survival rate is about 65% (Sedlis, 1978; Deppe et al., 1980; Inal et al., 2004). Kosary and colleagues found in a cohort of 416 women with fallopian tube carcinoma 5 year-survival rates of 95% for stage I (n=102), 75% for stage II (n=29), 69% for stage III (n= 52) and 45% for stage IV (n=151) (Kosary and Trimble, 2002). that these areas may contain putative tumor suppressor genes (Jongsma et al., 2002). Different authors (see above) found that immunohistochemical or PCR-based positivity for p53 alterations correlates with shorter survival (Hellstrom et al., 1994; Zheng et al., 1997; Rosen et al., 2000). Genetics BRCA1 (breast cancer 1, early onset) Note Fallopian tube carcinomas can manifest as a consequence of the hereditary breast-ovarian cancer syndrome. They are associated with BRCA1 and BRCA2 mutations. In a cohort of 44 cases of fallopian tube carcinoma, 11% of the patients were positive for BRCA1 mutation and 5% were positive for BRCA2 mutations. Of the patients who received their diagnosis before the age of 55 years, 28% (5/18) were BRCA positive. First degree relatives of fallopian tube cancer patients show an increased risk for early breast and ovarian cancer (Aziz et al., 2001). A BRCA1-carrier patient undergoing prophylactic salpingo-oophorectomy showed a fallopian tube cancer (Hartley et al., 2000). A positive family history of fallopian tube carcinoma was predictive for BRCA1 mutation in 26 Canadian breast-ovarian cancer families (Tonin et al., 1995). Friedman et al. reported fallopian tube carcinomas in 2 of 12 families with BRCA1 mutations (Friedman et al., 1995). Tonin et al. found BRCA1 mutations in four Ashkenazi Jewish breastovarian cancer families with fallopian tube carcinoma (Tonin et al., 1996). Zweemer and colleagues detected fallopian tube carcinomas in 2 of 23 families with known BRCA1 mutations (Zweemer et al., 2000). Thus, genetic evaluation should become part of the diagnostics for patients with fallopian tube carcinomas. In risk patients, prophylactic oophorectomy should be accompanied by salpingectomy (Aziz et al., 2001). And whether salpingectomy without oophorectomy is sufficient treatment will be analyzed in the clinical trials yet to come. Jongsma and colleagues reported frequent loss of heterozygosity (LOH) on chromosome 13 in BRCA1associated cases of fallopian tube carcinomas indicating Location 17q21 DNA / RNA 6 different mRNA variants that undergo alternative splicing. Splicing influences intracellular function and location. According to ENTREZ Gene, BRCA1 starts at NC_000017.10 (41196312..41277500, complement), Spidey (mRNA to genomic sequence alignment tool, http://www.ncbi.nlm.nih.gov/spidey) finds 24 exons. The mRNA consists of ~81.2kb. Protein The encoded protein functions as intracellular tumor suppressor with E3-ubiquitin ligaseand phosphopeptide binding activity. As a transcription factor, it is a DNA damage sensor forming (together with other proteins) the BRCA1-associated genome surveillance complex (BASC). Germline mutations lead to the familiar breast and ovarian cancer syndrome with highly increased risk for cancer development. Working together with RNA polymerase II, the protein has an important role in transcription, DNA repair of double-stranded breaks, and recombination. There are five different protein isoforms. Isoform 1 is the biggest with 1863 amino acids and 220 kDa. The highest expression of BRCA1 is found in the ovaries, thymus and testes. Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) Cytogenetics Note In BRCA1-related cases of ovarian and fallopian tube carcinoma, loss of heterozygosity (LOH) studies revealed high LOH frequencies on chromosome 13q11, 13q14, 13q21, 13q22-23, 13q32 and 13q32-4 that were independent of type of BRCA1 mutation, stage and grade. The authors suggested the long arm of chromosome 13 to contain putative tumor suppressor genes (Jongsma et al., 2002). Genes involved and proteins BRCA2 (breast cancer 2, early onset) Location 13q12.3 DNA / RNA According to Spidey, BRCA2 has 27 exons. The mRNA spans about 84.2 kb. In exon 11, the BRC repeats are encoded. 782 Fallopian tube tumors: an overview Stein RG, et al. Protein Also BRCA2 is involved in DNA stability, especially the double strand repair. The several BRC motifs in the protein bind the RAD51 recombinase and thus enable DNA repair. The protein consists of 3418 amino acids with a weight of 384 kDa. Note Tumor protein p53. DNA / RNA 11 exons, 8 transcript variants encoding 7 protein isoforms (http://www.ncbi.nlm.nih.gov/gene/7157#referencesequences). Protein p53 is a tumor suppressor protein that is synthesized in response to cellular stress. It causes cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism via DNA binding. The binding of p53 leads to transcriptional activation of several genes. Mutations are known from several human tumors and also for hereditary tumor syndroms like Li-FraumeniSyndrome. Transcription activation is triggered by a homo-tetrameric p53 complex in which mutant isoforms are dominant over the wild-type protein. Moreover, functional p53 induces its own degradation (with a half-life of 15-30 min) whereas mutant p53 accumulates and thus enables immunohistochemical detection. Examining a cohort of 43 patients with fallopian tube carcinoma, Lacy et al. found immunohistochemical positivity for c-erbB-2 (HER-2/neu) overexpression in 26% and p53 positivity in 61% of these tumors, but no significant correlation with survival (Lacy et al., 1995). Others, however, described p53 immunohistochemical positivity to be associated with shorter survival (Zheng et al., 1997; Rosen et al., 2000) whereas FIGO stages were not predictive for the outcome in this cohort of 63 patients (Rosen et al., 2000). Using 52 cases of fallopian tube carcinoma and 10 normal fallopian tubes, Zheng et al. investigated the p53 status based on immunohistochemistry and polymerase chain reaction-single-strand conformation polymorphisms (PCR-SSCP) and suggested that p53 alterations play a role in early tumor progression as they are not restricted to late stages (Zheng et al., 1997). Chung and colleagues found that survival neither correlated with immunohistochemical p53 positivity nor with cMyc overexpression (which occured in 61%). However, the statistical power of this study was limited by the small cohort of 18 patients (Chung et al., 2000). STK11 (serine/threonine kinase 11) Location 19p13.3 Note Mutation of this tumor suppressor gene causes the autosomal dominant Peutz-Jeghers-Syndrome which is characterized by intestinal polyposis and pigmented naevi as well as increased tumor risk (Jeghers et al., 1949; Giardiello et al., 1987). The protein is regulated by androgens and estrogen in adipocytes (McInnes et al., 2012). DNA / RNA The gene consists of 10 exons which encompass 23 kb. Protein The protein regulates cell polarity and functions as a tumor suppressor. It consists of 433 amino acids with a weight of 48.6 kDa. ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)) Location 17q12 Note Other names: HER-2/neu, c-erbB-2. DNA / RNA 31 exons, 2 mRNA variants encoding 2 proteins: isoform a and b. Protein This protein is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. It forms heterodimers with other EGFRs that (unlike ErbB-2) have a ligand binding domain and can thus initiate intracellular signaling leading to activation of pathways such as mTOR or PI3K. Overexpression is known for several cancers such as breast and ovarian but also fallopian tube carcinomas. Based on a cohort of 43 patients with fallopian tube carcinoma, Lacy et al. reported immunohistochemical positivity for c-erbB-2 (HER-2/neu) overexpression in 26% and p53 positivity in 61% of all cases. They could not find any correlation with survival (Lacy et al., 1995). MYC (v-myc myelocytomatosis viral oncogene homolog (avian)) Location 8q24 DNA / RNA 3 exons, 1 variant, 1 isoform. Protein The protein plays a role in cell cycle and apoptosis. It functions as transcription factor. Overexpression is known in several cancers especially leukaemias and TP53 (tumor protein p53) Location 17p13.1 Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 783 Fallopian tube tumors: an overview Stein RG, et al. Tamimi HK, Figge DC. Adenocarcinoma of the uterine tube: potential for lymph node metastases. Am J Obstet Gynecol. 1981 Sep 15;141(2):132-7 lymphomas like Burkitt's lymphoma. Chung and colleagues found that survival neither correlated with immunohistochemical p53 positivity nor with cMyc overexpression (which occured in 61%). However, the statistical power of this study was limited by the small cohort of 18 patients (Chung et al., 2000). Voet RL, Lifshitz S. Primary clear cell adenocarcinoma of the fallopian tube: light microscopic and ultrastructural findings. Int J Gynecol Pathol. 1982;1(3):292-8 Osborne BM, Robboy SJ. Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. Cancer. 1983 Nov 15;52(10):1933-43 To be noted Note Acknowledgement: We would like to thank Prof. Dr. med. Eva Geißinger and Dr. med. Camelia-Maria Monoranu, Institute of Pathology at Würzburg University, for supporting this publication with histopathological material and helpful discussions. Dekel A, van Iddekinge B, Isaacson C, Dicker D, Feldberg D, Goldman J. Primary choriocarcinoma of the fallopian tube. Report of a case with survival and postoperative delivery. Review of the literature. Obstet Gynecol Surv. 1986 Mar;41(3):142-8 References McMurray EH, Jacobs AJ, Perez CA, Camel HM, Kao MS, Galakatos A. Carcinoma of the fallopian tube. Management and sites of failure. Cancer. 1986 Nov 1;58(9):2070-5 Gisser SD. Obstructing fallopian tube papilloma. Int J Gynecol Pathol. 1986;5(2):179-82 JEGHERS H, McKUSICK VA, KATZ KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med. 1949 Dec 29;241(26):1031-6 Stephenson TJ, Mills PM. Adenomatoid tumours: an immunohistochemical and ultrastructural appraisal of their histogenesis. J Pathol. 1986 Apr;148(4):327-35 Momtazee S, Kempson RL. Primary adenocarcinoma of the fallopian tube. Obstet Gynecol. 1968 Nov;32(5):649-56 Giardiello FM, Welsh SB, Hamilton SR et al.. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987 Jun 11;316(24):1511-4 Woodruff JD, Julian CG. Multiple malignancy in the upper genital canal. Am J Obstet Gynecol. 1969 Mar 15;103(6):81022 Maxson WZ, Stehman FB, Ulbright TM, Sutton GP, Ehrlich CE. Primary carcinoma of the fallopian tube: evidence for activity of cisplatin combination therapy. Gynecol Oncol. 1987 Mar;26(3):305-13 Boutselis JG, Thompson JN. Clinical aspects of primary carcinoma of the Fallopian tube: a clinical study of 14 cases. Am J Obstet Gynecol. 1971 Sep;111(1):98-101 Asmussen M, Kaern J, Kjoerstad K, Wright PB, Abeler V. Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases. Gynecol Oncol. 1988 Jun;30(2):183-6 Schiller HM, Silverberg SG. Staging and prognosis in primary carcinoma of the fallopian tube. Cancer. 1971 Aug;28(2):38995 Keeney GL, Thrasher TV. Metaplastic papillary tumor of the fallopian tube: a case report with ultrastructure. Int J Gynecol Pathol. 1988;7(1):86-92 Kurman RJ, Scully RE, Norris HJ. Trophoblastic pseudotumor of the uterus: an exaggerated form of "syncytial endometritis" simulating a malignant tumor. Cancer. 1976 Sep;38(3):1214-26 McCarthy JH, Aga R. A fallopian tube lesion of borderline malignancy associated with pseudo-myxoma peritonei. Histopathology. 1988 Aug;13(2):223-5 Henderson SR, Harper RC, Salazar OM, Rudolph JH. Primary carcinoma of the fallopian tube: difficulties of diagnosis and treatment. Gynecol Oncol. 1977 Jun;5(2):168-79 Peters WA 3rd, Andersen WA, Hopkins MP, Kumar NB, Morley GW. Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol. 1988 May;71(5):757-62 Carapeto R, Nogales FF Jr, Matilla A. Ectopic pregnancy coexisting with a primary carcinoma of the Fallopian tube: a case report. Int J Gynaecol Obstet. 1978-1979;16(3):263-4 Bartnik J, Powell WS, Moriber-Katz S, Amenta PS. Metaplastic papillary tumor of the fallopian tube. Case report, immunohistochemical features, and review of the literature. Arch Pathol Lab Med. 1989 May;113(5):545-7 Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am. 1978 Feb;58(1):121-9 Yoonessi M. Carcinoma of the fallopian tube. Obstet Gynecol Surv. 1979 Apr;34(4):257-70 Hirai Y, Kaku S, Teshima H, Shimizu Y, Chen JT et al.. Clinical study of primary carcinoma of the fallopian tube: experience with 15 cases. Gynecol Oncol. 1989 Jul;34(1):20-6 Deppe G, Bruckner HW, Cohen CJ. Combination chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol. 1980 Oct;56(4):530-2 King A, Seraj IM, Thrasher T, Slater J, Wagner RJ. Fallopian tube carcinoma: a clinicopathological study of 17 cases. Gynecol Oncol. 1989 Jun;33(3):351-5 Hanjani P, Petersen RO, Bonnell SA. Malignant mixed Mullerian tumor of the fallopian tube. Report of a case and review of literature. Gynecol Oncol. 1980 Jun;9(3):381-93 Muntz HG, Tarraza HM, Granai CO, Fuller AF Jr. Primary adenocarcinoma of the fallopian tube. Eur J Gynaecol Oncol. 1989;10(4):239-49 Saffos RO, Rhatigan RM, Scully RE. Metaplastic papillary tumor of the fallopian tube--a distinctive lesion of pregnancy. Am J Clin Pathol. 1980 Aug;74(2):232-6 Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol. 1989 Nov;35(2):236-9 Ober WB, Maier RC. Gestational choriocarcinoma of the fallopian tube. Diagn Gynecol Obstet. 1981 Fall;3(3):213-31 Rose PG, Piver MS, Tsukada Y. Fallopian tube cancer. The Roswell Park experience. Cancer. 1990 Dec 15;66(12):2661-7 Raju KS, Barker GH, Wiltshaw E. Primary carcinoma of the fallopian tube. Report of 22 cases. Br J Obstet Gynaecol. 1981 Nov;88(11):1124-9 Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 784 Fallopian tube tumors: an overview Stein RG, et al. Heller DS, Rubinstein N, Dikman S, Deligdisch L, Moss R. Adenomatous polyp of the fallopian tube. A case report. J Reprod Med. 1991 Jan;36(1):82-4 Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC. c-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer. 1995 Jun 15;75(12):2891-6 Muntz HG, Tarraza HM, Goff BA, Granai GO, Rice LW, Nikrui N, Fuller AF Jr. Combination chemotherapy in advanced adenocarcinoma of the fallopian tube. Gynecol Oncol. 1991 Mar;40(3):268-73 Tonin P, Moslehi R, Green R, Rosen B, Cole D, Boyd N, Cutler C, Margolese R, Carter R, McGillivray B. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet. 1995 May;95(5):545-50 Daya D, Young RH, Scully RE. Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a report of six cases. Int J Gynecol Pathol. 1992;11(2):122-30 Tresukosol D, Kudelka AP, Edwards CL, Fromm GL, Mante R, Kavanagh JJ. Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel. Gynecol Oncol. 1995 Aug;58(2):258-61 Baekelandt M, Kockx M, Wesling F, Gerris J. Primary adenocarcinoma of the fallopian tube. Review of the literature. Int J Gynecol Cancer. 1993 Mar;3(2):65-71 Aoyama T, Mizuno T, Andoh K, Takagi T, Mizuno T, Eimoto T. alpha-Fetoprotein-producing (hepatoid) carcinoma of the fallopian tube. Gynecol Oncol. 1996 Nov;63(2):261-6 Barakat RR, Rubin SC, Saigo PE, Lewis JL Jr, Jones WB, Curtin JP. Second-look laparotomy in carcinoma of the fallopian tube. Obstet Gynecol. 1993 Nov;82(5):748-51 Navani SS, Alvarado-Cabrero I, Young RH, Scully RE. Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases. Gynecol Oncol. 1996 Dec;63(3):371-8 Jacoby AF, Fuller AF Jr, Thor AD, Muntz HG. Primary leiomyosarcoma of the fallopian tube. Gynecol Oncol. 1993 Dec;51(3):404-7 Tonin P, Weber B, Offit K, Couch F et al.. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov;2(11):1179-83 Puls LE, Davey DD, DePriest PD, Gallion HH, van Nagell JR Jr, Hunter JE, Pavlik EJ. Immunohistochemical staining for CA125 in fallopian tube carcinomas. Gynecol Oncol. 1993 Mar;48(3):360-3 Zheng W, Wolf S, Kramer EE, Cox KA, Hoda SA. Borderline papillary serous tumour of the fallopian tube. Am J Surg Pathol. 1996 Jan;20(1):30-5 Rosen A, Klein M, Lahousen M, Graf AH, Rainer A, Vavra N. Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Br J Cancer. 1993 Sep;68(3):605-9 Alvarado-Cabrero I, Navani SS, Young RH, Scully RE. Tumors of the fimbriated end of the fallopian tube: a clinicopathologic analysis of 20 cases, including nine carcinomas. Int J Gynecol Pathol. 1997 Jul;16(3):189-96 Uehira K, Hashimoto H, Tsuneyoshi M, Enjoji M. Transitional cell carcinoma pattern in primary carcinoma of the fallopian tube. Cancer. 1993 Oct 15;72(8):2447-56 Amos CI, Bali D, Thiel TJ, Anderson JP, Gourley I, Frazier ML, Lynch PM, Luchtefeld MA, Young A, McGarrity TJ, Seldin MF. Fine mapping of a genetic locus for Peutz-Jeghers syndrome on chromosome 19p. Cancer Res. 1997 Sep 1;57(17):3653-6 Cheung AN, Young RH, Scully RE. Pseudocarcinomatous hyperplasia of the fallopian tube associated with salpingitis. A report of 14 cases. Am J Surg Pathol. 1994 Nov;18(11):112530 Muggia FM, Hainsworth JD, Jeffers S, Miller et al.. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997 Mar;15(3):987-93 Hellström AC, Hue J, Silfverswärd C, Auer G. DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer. Int J Gynecol Cancer. 1994 Nov;4(6):408-413 Zabernigg A, Müller-Holzner E, Gasc JM, Gattringer C. An unusual case of a renin-producing tumour of the fallopian tube. Eur J Cancer. 1997 Sep;33(10):1709 Pectasides D, Barbounis V, Sintila A, Varthalitis I, Dimitriadis M, Athanassiou A. Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy. Am J Clin Oncol. 1994 Feb;17(1):68-71 Zheng W, Sung CJ, Cao P, Zhang ZF, Cai R, Godwin TA, Kramer EE, Lauchlan SC. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol Oncol. 1997 Jan;64(1):38-48 Seidman JD. Mucinous lesions of the fallopian tube. A report of seven cases. Am J Surg Pathol. 1994 Dec;18(12):1205-12 Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998 Oct;16(10):3345-52 Woolas R, Jacobs I, Davies AP, Leake J, Brown C, Grudzinskas JG, Oram D. What is the true incidence of primary fallopian tube carcinoma? Int J Gynecol Cancer. 1994 Nov;4(6):384-388 Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995 Nov;26(11):1260-7 Hoskins P, Eisenhauer E, Beare S, Roy M et al.. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998 Jun;16(6):2233-7 Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995 Dec;57(6):1284-97 Vaughan MM, Evans BD, Baranyai J, Weitzer MJ. Survival of patients with primary fallopian tube carcinoma. Int J Gynecol Cancer. 1998 Jan;8(1):16-22 Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999 Mar;72(3):367-79 Gollard R, Kosty M, Bordin G, Wax A, Lacey C. Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations. Gynecol Oncol. 1995 Dec;59(3):412-22 Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) 785 Fallopian tube tumors: an overview Stein RG, et al. Klein M, Rosen AC, Lahousen M, Graf AH, Rainer A. Lymphadenectomy in primary carcinoma of the Fallopian tube. Cancer Lett. 1999 Dec 1;147(1-2):63-6 Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol. 2001 Jan;80(1):16-20 Li S, Zimmerman RL, LiVolsi VA. Mixed malignant germ cell tumor of the fallopian tube. Int J Gynecol Pathol. 1999 Apr;18(2):183-5 Heatley MK. Polyp of the fallopian tube. Pathology. 2001 Nov;33(4):538-9 Inoue T, Nabeshima K, Shimao Y, Akiyama Y, Ohtsuka T, Koono M. Tubal ectopic pregnancy associated with an adenomatoid tumor. Pathol Int. 2001 Mar;51(3):211-4 Rosen AC, Klein M, Hafner E, Lahousen M, Graf AH, Reiner A. Management and prognosis of primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Gynecol Obstet Invest. 1999;47(1):45-51 Levite R, Fishman A, Kesler A, Altaras M, Gadoth N. Paraneoplastic cerebellar degeneration heralding fallopian tube adenocarcinoma. Int J Gynecol Cancer. 2001 MarApr;11(2):169-71 Su YN, Cheng WF, Chen CA, Lin TY, Hsieh FJ, Cheng SP, Hsieh CY. Pregnancy with primary tubal placental site trophoblastic tumor--A case report and literature review. Gynecol Oncol. 1999 May;73(2):322-5 Jongsma AP, Piek JM, Zweemer RP, Verheijen RH, Klein Gebbinck JW, van Kamp GJ, Jacobs IJ, Shaw P, van Diest PJ, Kenemans P. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol. 2002 Oct;55(5):305-9 Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM. Carcinoma of the fallopian tube. Cancer. 2000 Nov 15;89(10):2076-84 Chung TK, Cheung TH, To KF, Wong YF. Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. Gynecol Obstet Invest. 2000;49(1):47-51 Klein M, Graf AH, Rosen A, Lahousen M, Hacker GW. Tumor progression, histologic grading and DNA-ploidy as predictive factors of lymphogenous metastasis in primary carcinoma of the Fallopian tube. Cancer Lett. 2002 Mar 28;177(2):209-14 Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3093100 Kosary C, Trimble EL. Treatment and survival for women with Fallopian tube carcinoma: a population-based study. Gynecol Oncol. 2002 Aug;86(2):190-1 Hartley A, Rollason T, Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol (R Coll Radiol). 2000;12(1):58-9 Alvarado-Cabrero I, Cheung A, Caduff R.. Tumours of the Fallopian Tube. World Health Organization classification of tumors: Tumors of the breast and female genital organs, IARC Press, 2003. Ichikawa Y, Tsunoda H, Nishide K, Nishida M, Kubo T. Metachronous carcinoma of the vulva and fallopian tube. Gynecol Oncol. 2000 Apr;77(1):206-9 Colgan TJ.. Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol. 2003 Apr;22(2):109-20. (REVIEW) Piura B, Rabinovich A. Primary carcinoma of the fallopian tube: study of 11 cases. Eur J Obstet Gynecol Reprod Biol. 2000 Aug;91(2):169-75 Gurbuz Y, Ozkara SK.. Immunohistochemical profile of serous papillary cystadenofibroma of the fallopian tube: a clue of paramesonephritic origin. Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):153-5. Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, Reiner A. p53 expression in fallopian tube carcinomas. Cancer Lett. 2000 Aug 1;156(1):1-7 Riska A, Leminen A, Pukkala E.. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer. 2003 May 1;104(5):643-5. Schneider C, Wight E, Perucchini D, Haller U, Fink D. Primary carcinoma of the fallopian tube. A report of 19 cases with literature review. Eur J Gynaecol Oncol. 2000;21(6):578-82 Trimbos JB, Parmar M, Vergote I, Guthrie D et al.. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. Takeshima N, Hasumi K. Treatment of fallopian tube cancer. Review of the literature. Arch Gynecol Obstet. 2000 Jul;264(1):13-9 Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P. Inal MM, Hanhan M, PIlanci B, Tinar S.. Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital. Int J Gynecol Cancer. 2004 JulAug;14(4):595-9. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol. 2000 Jan;76(1):45-50 Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS.. Primary fallopian tube carcinoma. Obstet Gynecol Surv. 2005 Apr;60(4):247-52. (REVIEW) Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001 Mar;80(3):341-5 Tanaka Y, Suzuki N, Takao M, Ichikawa A, Susumu N, Aoki D.. Paraneoplastic cerebellar degeneration with fallopian tube adenocarcinoma. Gynecol Oncol. 2005 Nov;99(2):500-3. Epub 2005 Aug 29. Demopoulos RI, Aronov R, Mesia A. Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol. 2001 Apr;20(2):128-32 Pectasides D, Pectasides E, Economopoulos T.. Fallopian tube carcinoma: a review. Oncologist. 2006 Sep;11(8):902-12. (REVIEW) Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol. 2001 May;81(2):150-9 Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) Kindelberger DW, Lee Y, Miron A, Hirsch MS et al.. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007 Feb;31(2):161-9. 786 Fallopian tube tumors: an overview Stein RG, et al. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP.. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007 Jan;211(1):26-35. Selby KJ, Warner J, Klempner S, Konstantinopoulos PA, Hecht JL.. Anti-Yo antibody associated with occult fallopian tube carcinoma. Int J Gynecol Pathol. 2011 Nov;30(6):536-8. doi: 10.1097/PGP.0b013e3182237ca6. Vang RWJ.. Diseases of the fallopian tube and paratubal region. Blaustein's pathology of the female genital tract. New York, Springer. 2011. Stewart SL, Wike JM, Foster SL, Michaud F.. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol. 2007 Dec;107(3):392-7. Epub 2007 Oct 24. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR.. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP.. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008 Sep 1;26(25):4160-5. doi: 10.1200/JCO.2008.16.4814. Piek JM, van Diest PJ, Verheijen RH.. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol. 2008;622:79-87. doi: 10.1007/978-0-387-68969-2_7. (REVIEW) Etoh T, Watanabe Y, Imaoka I, Murakami T, Hoshiai H.. Primary adenomyoma of the fallopian tube mimicking tubal malignant tumor. J Obstet Gynaecol Res. 2012 Apr;38(4):7213. doi: 10.1111/j.1447-0756.2011.01764.x. Epub 2012 Mar 2. No authors listed.. TNM classification of malignant tumors. John Wiley Sons: New York. UICC, 2009. Folkins AK, Jarboe EA, Roh MH, Crum CP.. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol. 2009 Jun;113(3):391-6. doi: 10.1016/j.ygyno.2009.01.013. Epub 2009 Feb 23. (REVIEW) Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM.. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3921-6. doi: 10.1073/pnas.1117135109. Epub 2012 Feb 13. No authors listed.. Cancer staging manual. Springer NY Dordrecht Heidelberg London. AJCC (2010). Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih IeM.. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010 Jun;34(6):829-36. doi: 10.1097/PAS.0b013e3181dcede7. Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr.. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One. 2012;7(11):e49829. doi: 10.1371/journal.pone.0049829. Epub 2012 Nov 26. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R.. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010 Oct;34(10):1407-16. doi: 10.1097/PAS.0b013e3181ef7b16. McInnes KJ, Brown KA, Hunger NI, Simpson ER.. Regulation of LKB1 expression by sex hormones in adipocytes. Int J Obes (Lond). 2012 Jul;36(7):982-5. doi: 10.1038/ijo.2011.172. Epub 2011 Aug 30. Xian W, Miron A, Roh M, Semmel DR, Yassin Y et al.. The LiFraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol. 2010 Jan;220(1):17-23. doi: 10.1002/path.2624. Pujade-Lauraine E, Weber B, Reuss A et al.. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). ASCO 2012 Annual Meeting. Dietl J, Wischhusen J.. The forgotten fallopian tube. Nat Rev Cancer. 2011 Mar;11(3):227; author reply 227. doi: 10.1038/nrc2946-c1. Wagner U, Marth C, Largillier R, Kaern J et al.. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26. Dietl J, Wischhusen J, Hausler SF.. The post-reproductive Fallopian tube: better removed? Hum Reprod. 2011 Nov;26(11):2918-24. doi: 10.1093/humrep/der274. Epub 2011 Aug 16. (REVIEW) Vang R, Shih IeM, Kurman RJ.. Fallopian tube precursors of ovarian lowand high-grade serous neoplasms. Histopathology. 2013 Jan;62(1):44-58. doi: 10.1111/his.12046. Seidman JD, Zhao P, Yemelyanova A.. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011 Mar;120(3):470-3. doi: 10.1016/j.ygyno.2010.11.020. Epub 2010 Dec 14. Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11) This article should be referenced as such: Stein RG, Diessner J, Hönig A, Wischhusen J, Dietl J. Fallopian tube tumors: an overview. Atlas Genet Cytogenet Oncol Haematol. 2013; 17(11):773-787. 787